Immuno-Oncology Summit

We are pleased to invite you to the Immuno-Oncology Summit, scheduled for October 3rd -4th, 2018, in Vienna, Austria.

This Summit is focused on Immuno-Oncology this rapidly evolving field and the most promising new cancer treatment approach since the development of the first chemotherapies.

It will bring together decision makers and industry leaders with both scientific and commercial interests to expand the scientific horizons of Immuno-Oncology, and discuss the latest advancements and improvements in research and development, business opportunities in partnering and investing. We will discuss key findings, critical insights, as well as recommendations for accelerating development in the field.

It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Vienna, this coming October!

Key Practical Learning Points of the Summit:

  • Advanced methods, developments and strategies in Immuno-Oncology
  • The success of antibodies in therapeutics and engineering
  • The true potential of the next generation immune checkpoint pathways
  • Preclinical Science
  • Clinical Research and clinical trials in therapeutic areas
  • Translation of Immuno-Oncology
  • Revolutionary cancer treatment with personalised cancer vaccines
  • Managing unique immune-mediated adverse reactions and toxicity effects
  • Regulatory aspects of the EU and the rest of the world
  • New industry trends

Who Should Attend:

Chief Executives, Directors, Vice Presidents, Department Heads, Leaders, Scientists, Investigators and Managers specialising in:

  • Oncology
  • Clinical Diagnostics
  • Drug Discovery
  • Drug Delivery
  • Antibody Engineering
  • Antibody Discovery
  • Cancer Immunotherapy
  • Immuno-Oncology
  • Haematology
  • Translational Medicine Genetics and Genomics
  • Bioinformatics
  • Cancer Genomics
  • Infection and Immunity
  • Cell Therapy Research
  • Cell & Gene Therapy
  • Preclinical Development
  • Tumour Immunology
  • Pathology
  • Vaccines Development
Speakers
Media partners

Previous Year Attendees

  • National Center for Tumor Diseases (NCT) Heidelberg, Germany

  • Hamamatsu Tissue Imaging and Analysis Center, BIOQUANT, Germany
    Scientific Director

  • Genentech/Roche, Switzerland
    Senior Medical Director, Cancer Immunotherapy

  • QuintilesIMS, UK
    Senior Director, Therapeutic Science & Strategy

  • Shire, Austria
    Director R&D, Antibody Technology

  • Roche Innovation Center Zurich, Switzerland
    Pharmacology Research Area

  • Silenseed LTD, Israel
    CEO

  • University of Southampton, UK
    Associate Professor in Oncology, Cancer Sciences Unit

  • GlaxoSmithKline, UK
    Head of Discovery & New Technologies, Oncology Cell Therapy Unit, Oncology R&D

  • Novartis Pharma AG, Switzerland
    Global Clinical Leader, Oncology Clinical Development

  • AstraZeneca, UK
    Medical Director IO-Gmed

  • AMGEN GmbH, Germany
    Medical Development Director - TA Bone/Inflammation/Neuroscience

  • GE Healthcare, UK
    Product Leader, Cell Therapy

  • NanoTemper Technologies GmbH Munich, Germany
    Senior Application Scientist & Sales

  • Paul-Ehrlich-Institut Langen, Germany
    Head of Tissue Engineering & Somatic Cell Therapeutics

  • Glythera Ltd, UK
    Senior Development Scientist

  • Merck Serono S.p.A., Italy
    Biotech Scientific Manager

  • Agensys, an affiliate of Astellas Pharma, Inc., USA
    Senior Director Pharmacology

  • eTheRNA immunotherapies NV, Belgium
    Chief Scientific Officer

  • Lonza Cologne GmbH, Germany
    Sales Specialist

  • IPSEN Innovation SAS, France
    Senior Regulatory Product Manager

  • Novartis Pharma GmbH, Germany
    Medical Advisor

  • Ablynx NV, Belgium
    Senior Research Fellow

  • Charles River, UK
    Senior Director Scientific Alliances

  • Orion Clinical Services Ltd., UK
    Associate Medical Director

  • NeoGenomics Laboratories, USA
    Vice President Pharma Services, International Sales & Business Development

  • BioNTech Small Molecules GmbH, Germany
    Head of Small Molecules

  • Personalis, Inc., USA
    Executive Account Manager D/A/CH

  • Illumina GmbH, Germany
    District Marketing Manager, Central Europe

  • Lonza AG, Switzerland
    R&T Pharma & Biotech

  • Advanced Cell Diagnostics SRL, Italy
    Senior Director Europe, ACD SRL

  • Symphogen Inc., USA
    V.P of Project Management & Clinical Operation

  • Illumina Cambridge Ltd, UK
    Director, Business Development

  • Myriad RBM, Inc., USA
    Director, Business Development

  • HISTALIM, SARL, France
    Project Manager

  • Heraeus Deutschland GmbH & Co. KG, Germany
    Global Head Projectmanagement Pharmaceutical Ingredients

  • Crown Bioscience Inc., USA
    Director of Business Development

  • Invectys SA, France
    CEO

  • Glycotope GmbH, Germany
    CMO

  • Bayer Pharma AG, Germany
    Head Clinical Pharmacology Oncology

  • Polypure AS, Norway
    COO

  • ProteinSimple, USA
    Global Pharma and Partners Manager - Simple Plex